Business Context and Reporting Period
Lifecore Biomedical, Inc. (LFCR) filed this Form 8-K on October 3, 2024, reporting a material definitive agreement and the closing of a private equity offering. The filing also references the announcement of financial results for the fiscal quarter ended August 25, 2024, issued on October 4, 2024.
Key Financial Metrics and Transaction Details
- Offering Proceeds: Approximately $24.3 million in aggregate gross proceeds.
- Shares Issued: 5,928,775 shares of common stock.
- Price Per Share: $4.10.
- Key Purchasers: Entities affiliated with Legion Partners Asset Management, Greenhaven Road Investment Management, Wynnefield Capital, and 325 Capital.
- Related Party Transactions: Board members Christopher Kiper (affiliated with Legion Partners) and Nelson Obus (affiliated with Wynnefield Capital) are connected to purchasing entities.
- Financial Results: Specific revenue, profit, cash flow, margin, debt, and liquidity figures for the quarter ended August 25, 2024, are not provided in the text of this filing; they are contained in the referenced press release (Exhibit 99.1).
Material Changes and Agreements
The primary material change is the entry into a Stock Purchase Agreement on October 3, 2024, resulting in the immediate issuance of new equity. The offering was exempt from registration under Section 4(a)(2) of the Securities Act. The Company has agreed to file a resale registration statement within 30 calendar days of the closing and use reasonable efforts to make it effective within 60 days (or 90 days in the event of a full SEC review).
Guidance, Risks, and Contingencies
- Liquidated Damages: The Purchase Agreement stipulates that the Company must make payments as liquidated damages to Purchasers if the resale registration statement is not timely made effective or becomes unavailable for resale, subject to exceptions.
- Registration Rights: Purchasers were granted piggyback registration rights and indemnification against certain losses and liabilities under registration statements.
- Investor Presentation: The Company released investor presentation materials on October 4, 2024, which are furnished as Exhibit 99.2 but are not deemed "filed" for Section 18 liability purposes.
Investor Verification Checklist
- Verify the specific financial performance metrics (revenue, net income, cash flow) in the press release (Exhibit 99.1) referenced in Item 2.02.
- Review the full Stock Purchase Agreement (Exhibit 10.1) for detailed terms regarding liquidated damages and registration obligations.
- Confirm the status of the resale registration statement filing and its expected effectiveness date.
- Assess the impact of the new share issuance on existing shareholder dilution.
- Examine the related party disclosures regarding Board members' affiliations with the Purchasers.